Experimental Pharmacology and Toxicology
The ExPT Lab works in the field of redox imbalance in development and disease. Increased oxidative stress - i.e. an imbalance in the cellular redox homeostasis - is observed during e.g. development, aging and inflammation and has been associated with several chronic diseases including atherosclerosis, liver steatosis, diabetes and cancer.T
With particular focus on in vivo experimentation including animal models, we study the effects of oxidative insults on the redox homeostasis as well as the possible benefit of intervention with bioactive compounds. We aim to integrate biochemical, pathological and functional outcomes.
Our primary goal is to understand the role and mechanism of altered redox status in disease development and progression and thereby pave the road for better prevention strategies and pharmacotherapy. Key projects involve early brain development impairment and several chronic diseases including diabetes and cardiovascular disease.
The major focus of the lab, involving many both internal and external projects, is the study of the molecular, pathological and functional consequences of marginal (subclinical) vitamin C deficiency (as opposed to chronic severe vitamin C deficiency that inevitably leads to scurvy).
The condition is common in humans but has been given little attention in the literature in spite of overwhelming epidemiological evidence of its consistent association to morbidity. Our two main areas of interest are early brain development and cardiovascular disease.
Our lab is among the leading labs in the world in this particular field. Besides our own research using the guinea pigs as animal model, we participate in many national and international experimental and clinical studies. Other interests within deficiency toxicology include vitamin D deficiency and kwashiorkor.
These projects involve development and validation of biomarkers of oxidative stress in the vasculature in a variety of species (mice, rats, guinea pigs, dogs, pigs, humans) as well as testing drugs and drug candidates in animal models of disease.
Particular emphasis is on oxidative stress in conditions related to the metabolic syndrome cluster and diabetes. Again, both animal models and human studies are carried out with special focus on translational aspects including characterization of model validity.
This work is pursued particularly with the purpose of validating cognitive measures in guinea pigs.
In relation to our interest in early brain development, we have recognized cognitive performance as an important functional outcome of impaired growth.
This work is pursued particularly with the purpose of validating cognitive measures in guinea pigs.
We have a fundamental interest in pharmacokinetic and -dynamic models.
Current projects include the non-linear absorption, distribution and elimination of vitamin C, clearance of biopharmaceuticals in hepatectomised and nephrectomised rats as well as in vivo imaging of drug action in mice and rats.
- The role of vitamin C deficiency in impaired brain development (www.lifepharm.dk , www.invivofarm.dk ), Jens Lykkesfeldt, Pernille Tveden-Nyborg, Stine Hasselholt, Maiken Marie Lindblad, Stine Norman Hansen (master student), Jytte Overgaard Larsen.
- Relative importance of liver and kidney in the clearance of rFVIIa (www.lifepharm.dk), Jens Lykkesfeldt, Bill Vestergaard, Henrik Agersø (Novo Nordisk).
- Metabolic changes induced in non-diabetic rats following chronic hyperinsulinaemic hypoglycaemia (www.lifepharm.dk), Jens Lykkesfeldt, Vivi Jensen, Pernille Christensen (master student), Ingrid Bøgh Brück (Novo Nordisk).
- Effect and mode of action of liraglutide intervention on hyperglycaemia mediated oxidative stress in diabetic and diabetic complications animal models (www.lifepharm.dk), Jens Lykkesfeldt, Karen Ekkelund Petersen, Kirsten Raun & Günaj Rakipovski (Novo Nordisk).
- Animal models of Kwashiorkor; Thomas Thymann (KU-SCIENCE), Christian Fabiasen, Henrik Friis, Jens Lykkesfeldt, Jørgen Koch and many others.
- Immuno-toxicological reactions caused by biopharmaceuticals formulated as nanoparticles (www.invivofarm.dk), Jens Lykkesfeldt, Kristina Bram Knudsen, Helle Northeved (Lundbeck), Anders Permin (DTU), Steffen Loft, Peter Møller, Martin Roursgaard and many others.
- Characterization of real time in-vivo coagulation and clot formation by fluorescence microscopy in haemophilia treatments (www.lifepharm.dk ), Pernille Tveden-Nyborg, Jens Lykkesfeldt, Caroline Røddik, Christian Sommer (Novo Nordisk).
- Oxidative stress in surgery, ischemia-reperfusion and sepsis (several projects); Ismail Gögenur (Copenhagen University Hospital, Herlev), Jacob Rosenberg, Jens Lykkesfeldt and many others.
- Vitamin C as an anti-cancer drug (www.clinicaltrials.gov); Kari Mikines (Copenhagen University Hospital, Herlev), Torben Nielsen, Martin Højgaard, Jens Lykkesfeldt, Henrik Enghusen Poulsen (Copenhagen University Hospital).
- Obesity, inflammation and oxidative stress - a randomized placebo-controlled trial; Gladys Block (University of California, Berkeley), Jens Lykkesfeldt and many others.
- Treatment of oxidative stress in cystic fibrosis patients; Oana Ciofu, Niels Højby, Jens Lykkesfeldt, Henrik Enghusen Poulsen and many others.
- Effects of diesel exhaust particle exposure on oxidative stress in the vasculature; Steffen Loft, Peter Møller, Jens Lykkesfeldt and many others.
- Systemic oxidative stress and vascular dysfunction by oral exposure to particles (KU-SUND merger scholarship), Peter Møller, Jens Lykkesfeldt, Majid Sheykhzade, Ditte Marie Jensen.
- Cognitive and emotional consequences of diet-induced obesity in rats ((www.lifepharm.dk)), Dorte Bratbo Sørensen, Pernille Tveden-Nyborg, Bjørn Forkman, David Sarruf (Novo Nordisk), Alessandro Virtouso.
- Development and characterization of a diabetic and atherosclerotic rodent animal model (www.lifepharm.dk), Axel Kornerup Hansen, Ida Rune Sørensen, Jens Lykkesfeldt, Bidda Rolin (Novo Nordisk), Berit Christoffersen (Novo Nordisk)
- New in vivo cardiovascular biomarkers in an animal model of chronic mitral regurgitation (www.lifepharm.dk), Lisbeth Høier Olsen, Maria Reimann, Jens Lykkesfeldt and many others.
- Development and characterization of an atherosclerotic minipig model (www.lifepharm.dk), Lisbeth Høier Olsen, Trine Pagh Ludvigsen, Jens Lykkesfeldt, Henrik Duelund Pedersen, Berit Ø. Christoffersen (Novo Nordisk).
- Establishment of a venous bleeding model in haemophilia A mice for evaluation of haemostatic effect of pro-coagulant compounds (www.invivofarm.dk), Jens Lykkesfeldt, Anne Pastoft, Brian Lauritzen (Novo Nordisk).
- The high fat fed guinea pig as a model for human dyslipidemia and pre-diabetes (www.lifepharm.dk), Jens Lykkesfeldt, David Høiland Ipsen, Pernille Tveden-Nyborg, Bidda Rolin, Günaj Rakipovski (Novo Nordisk).
- The impact of neonatal Fc receptor and disease processes on in vivo distribution of biopharmaceuticals using advanced imaging technologies (www.lifepharm.dk), Jens Lykkesfeldt, Henrik Agersø, Maj Petersen (Novo Nordisk), Laura Hvidsten.
- In vivo regulation of vitamin C transport in the brain during deficiency (www.invivofarm.dk), Pernille Tveden-Nyborg, Maiken Marie Lindblad, Jens Lykkesfeldt.
- The development of biomarkers of vascular oxidative stress; (www.lifepharm.dk) Jens Lykkesfeldt, Anis Anous.
- The bioavailability and distribution of vitamin C; Jens Lykkesfeldt, Pernille Tveden-Nyborg, Henriette Frikke-Schmidt, Stine Hasselholt, Maiken Lindblad.
Researchers
| Name | Title | Phone | |
|---|---|---|---|
| Search in Name | Search in Title | Search in Phone | |
| Charlotte Winberg Larsen | Attendant | +4535333165 | |
| Jens Lykkesfeldt | Professor | +4535333163 | |
| Josephine Skat-Rørdam | Postdoc | +4535330210 | |
| Kamilla Pedersen | PhD Student | +4530126941 | |
| Pernille Tveden-Nyborg | Associate Professor | +4535333167 |
Contact
Group leader
Assoc. prof. Pernille Tveden-Nyborg
PH: +45 35 33 31 67
ptn@sund.ku.dk
Secretariat:
Helle Vinberg +45 35 33 27 08
Graduate Programme
Experimental Pharmacology and Toxicology Lab is home to the Graduate Programme for In Vivo Pharmacology and Experimental Animals (www.invivofarm.dk ) and the LIFEPHARM Centre (www.lifepharm.dk).